CYCC Insider Trading Activity and SEC Form 4 Filings
CYCC insider trading summary
No open-market insider purchases or sales of Cyclacel Pharmaceuticals, Inc. (CYCC) have been reported on SEC Form 4 in the past 12 months.
Latest CYCC insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 5, 2025 | Khai Loon Kua | 10% Owner | Sell | $134K (19,054 @ $7.01) |
| Jul 30, 2025 | David E. Lazar | 10% Owner | Sell | $83K (6,750 @ $12.36) |
| Feb 26, 2025 | David E. Lazar | Interim CEO | Sell | $5.5M (194,628,820 @ $0.03) |
| Dec 21, 2023 | Paul McBarron | See Remarks | Buy | $6K (1,886 @ $3.31) |
| Dec 21, 2023 | Spiro George Rombotis | President and CEO | Buy | $20K (6,070 @ $3.31) |
| Nov 30, 2021 | Sam L Barker | Director | Sell | $43 (12 @ $3.57) |
| Nov 18, 2021 | Spiro George Rombotis | President and CEO | Buy | $18K (4,000 @ $4.50) |
| Aug 24, 2021 | Sam L Barker | Director | Buy | $5K (1,000 @ $5.00) |
| Jul 19, 2017 | Portfolio Services Ltd. | 10% Owner | Buy | $1.7M (850,000 @ $2.00) |
| Jul 19, 2017 | Kenneth Bryan Dart | 10% Owner | Buy | $1.7M (850,000 @ $2.00) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.